Market Overview

Markets are set to open higher Wednesday as chip stocks extend their bounce ahead of Nvidia’s earnings report after the close — the most anticipated catalyst of the week. Rising bond yields spooked markets Tuesday (-0.67% on the S&P 500), but pre-market futures are recovering on Target’s earnings beat and optimism that NVDA will deliver. The semiconductor complex is the clear leadership group today, with 12 of the top 20 gainers being chip-adjacent names, driven by a combination of analyst upgrades (MRVL, ALAB), U.S.-China trade hopes, and pre-NVDA positioning.

Top Movers

SLS (+18.18%) — $8.97 → $10.78 (+20.2% upside) Thesis: Clinical-stage biotech surging as its pivotal Phase 3 REGAL trial in AML reaches 78 of 80 required events — a binary catalyst readout is imminent. The stock is trading at its 6-month high with 1.4x average volume, showing genuine accumulation ahead of data. This is a pure event-driven trade with asymmetric payoff potential, but be warned — biotech binary events can destroy you. Levels: Exit at fib 1.272 extension ($10.78). Support at fib 236 retracement ($7.03) and 50-day SMA ($5.19).

ARM (+10.56%) — $246.71 → $298.97 (+21.2% upside) Thesis: Arm is ripping to fresh 6-month highs on the pre-NVDA semiconductor euphoria, but there’s substance here — the post-earnings narrative has shifted to royalty acceleration from AI inference chips, and the stock is attracting institutional accumulators at the $210-215 level according to research desks. FTC antitrust probe and a $3B ESOP shelf registration are headwinds, but the market doesn’t care today. Trading well above the 50-day SMA ($174.67) — this is a momentum name you ride, not fight. Levels: Exit at fib 1.272 extension ($298.97). Support at fib 236 retracement ($221.32), which aligns with the smart money accumulation zone.

ALAB (+9.18%) — $266.68 → $328.96 (+23.3% upside) Thesis: Astera Labs is a direct AI connectivity play that got an Evercore ISI “Buy” initiation with a raised price target, sending shares up 13% yesterday and continuing today. This is the picks-and-shovels play for AI data center interconnects — a structural winner, not just a sympathy trade. At 93.4% revenue growth, the 66x forward P/E looks less crazy than it appears (PEG ~0.7 on that growth rate). Trading at 6-month highs with no overhead resistance. Levels: Exit at fib 1.272 extension ($328.96). Support at fib 236 ($237.63) and 50-day SMA ($166.38).

MRVL (+8.09%) — $190.53 → $218.18 (+14.5% upside) Thesis: Wells Fargo raised its target to $195 (now breached) on AWS Trainium custom silicon momentum, and Oppenheimer is calling for upside to fiscal Q1 results. This is the best risk/reward semi name today — it has a specific fundamental catalyst (custom AI chips for hyperscalers), analyst upgrades with price targets still being raised, and clear technical room to run. At 34.5x forward P/E on 22% growth, it’s expensive vs. peers but justified by the AI custom silicon narrative. Levels: Exit at fib 1.272 extension ($218.18). Support at fib 236 ($160.47) and 50-day SMA ($133.31).

TJX (+5.18%) — $158.49 → $169.33 (+6.8% upside) Thesis: Beat Q1 estimates and raised full-year guidance — this is a real earnings catalyst, not sympathy. TJX is the defensive growth name in a market nervous about consumer spending; they’re gaining share as consumers trade down. RSI at 2.35 (!) suggests this stock was massively oversold heading into the print — this bounce has legs. Management is shrugging off high gas prices, which is exactly what you want to hear. Levels: Exit at fib 1.272 extension ($169.33). Support at 50-day SMA ($156.07) and fib 382 ($157.62).

MXL (+4.78%) — $99.39 → $126.54 (+27.3% upside) Thesis: MaxLinear has transformed from a boring broadband chip company into an AI data center connectivity play — up 442% in six months. New product launches (Washington TIA for 1.6T optical transceivers, Trinity 5G platform) are giving this story real substance. However, at 51.6x forward P/E on 43% growth and after this kind of run, you’re buying a crowded trade. The 20-day range from $34.25 to $102.27 tells you this is a highly volatile name — size accordingly. Levels: Exit at fib 1.272 extension ($126.54). Support at fib 236 ($81.21) and 50-day SMA ($43.59 — yes, that far below).

LPG (+3.74%) — $43.90 → $54.25 (+23.6% upside) Thesis: Dorian LPG crushed Q4 earnings estimates this morning, sending shares up 12% pre-market. Stronger VLGC freight market is the driver. This is a clean post-earnings breakout to 6-month highs on 1.85x average volume — the highest volume confirmation on today’s list. Shipping names can trend for weeks after an earnings reset. Levels: Exit at fib 1.272 extension ($54.25). Support at fib 236 ($41.70) and 50-day SMA ($35.50).

GH (+4.22%) — $102.33 → $127.80 (+24.9% upside) Thesis: FDA just approved Guardant Health’s newest blood cancer test — this is the kind of binary regulatory catalyst that can reset a stock’s trajectory. Q1 revenue grew 48% YoY to $301.7M, and the Shield colorectal cancer test is accelerating. RSI at 10.15 means this was deeply oversold before today’s news — the combination of oversold bounce + FDA approval is powerful. The insider sale last week was noise. Levels: Exit at fib 1.272 extension ($127.80). Support at fib 236 ($108.15) and 50-day SMA ($89.74).

SM (+3.70%) — $35.59 → $39.30 (+10.4% upside) Thesis: SM Energy hitting 52-week highs as the Civitas merger integration delivers better-than-expected production and 2x original synergy targets. Oil-levered E&P benefiting from constructive crude prices. Volume at 1.1x confirms mild conviction, but the setup is clean — breakout to new highs with production growth and cost synergies still coming through. Levels: Exit at fib 1.272 extension ($39.30). Support at fib 236 ($30.56) and 50-day SMA ($29.67).

Headlines to Watch

  • Nvidia reports after the close today — The single most important event for the semiconductor complex; a beat likely extends today’s chip rally, a miss could unwind everything above. Position sizing matters.
  • Fed April FOMC Minutes released today — After hot April CPI killed rate-cut hopes for 2026, the minutes will reveal how hawkish the committee really is. Rising yields were the #1 headwind Tuesday.
  • Target beats Q1 estimates but shares fall, raises sales guidance — Mixed signals on the consumer: TJX up, TGT down despite a beat. The market is distinguishing between winners and losers in retail.
  • FTC opens formal antitrust probe into ARM’s licensing practices — Could force licensing fee concessions that would directly hit ARM’s royalty revenue model. Worth monitoring for the entire chip ecosystem.
  • U.S.-China summit concluded without semiconductor breakthroughs — Explains Monday’s selloff in chip equipment names (IPGP, LSCC, ACMR). The lack of progress keeps export restriction uncertainty elevated.
  • Wells Fargo raises MRVL target to $195 on AWS Trainium momentum — Custom silicon for hyperscalers is becoming the consensus AI infrastructure thesis for 2026-2027.
  • Guardant Health (GH) receives FDA approval for new blood cancer test — Expands the addressable oncology testing market; this is a durable catalyst, not a one-day event.

Claude’s Top Picks

MRVL (+8.09% today, +7.07% week) — $190.53 → $218.18 (+14.5% upside) Valuation: At 34.5x forward P/E on 22% growth, PEG of ~1.6 — premium to peers but reasonable for a direct AI custom silicon beneficiary with hyperscaler contracts. Upside: Multiple analyst upgrades with targets being raised (Wells Fargo $195, Oppenheimer calling for upside), AWS Trainium deployment scaling, and fiscal Q1 results expected to beat. Risk: Already past Wells Fargo’s $195 target; if NVDA misses tonight, this gives back 10%+ immediately. Use fib 236 at $160.47 as stop.

GH (+4.22% today, +3.93% week) — $102.33 → $127.80 (+24.9% upside) Valuation: Not in comps data, but 48% revenue growth with a path to profitability on an FDA-expanded product suite is attractive for a diagnostics growth name. Upside: FDA approval of new blood cancer test + deeply oversold RSI (10.15) = classic mean-reversion setup with a fundamental catalyst. Revenue growing 48% with full-year guide 3.1% above consensus. Risk: Co-CEO sold $5M in stock last week; insider selling after a big approval can signal “good as it gets” — watch for more filings.

TJX (+5.18% today, +8.15% week) — $158.49 → $169.33 (+6.8% upside) Valuation: Defensive retail compounder with consistent execution — likely trading at ~20x forward earnings, cheap relative to its own history for this quality level. Upside: Raised full-year outlook, RSI at 2.35 is the most oversold reading on the entire list, and the consumer trade-down thesis is structural not cyclical. Risk: Only 6.8% to first fib extension target — smaller upside than others, but the risk/reward is excellent given the $156-157 support shelf. Lower beta pick.

LPG (+3.74% today, +10.77% week) — $43.90 → $54.25 (+23.6% upside) Valuation: Shipping names trade on earnings power and cash flow yield; post-beat, forward estimates likely rising, making this cheaper than it looks. Upside: Best volume confirmation (1.85x) on the list + earnings beat + breakout to new highs. Shipping stocks trend after earnings resets because analyst estimates take weeks to fully adjust. Risk: VLGC freight rates are cyclical and geopolitically sensitive; any de-escalation in Red Sea/Panama routing could compress rates quickly.

ALAB (+9.18% today, +19.01% week) — $266.68 → $328.96 (+23.3% upside) Valuation: 66x forward P/E looks expensive, but on 93.4% revenue growth the PEG is ~0.7 — genuinely cheap on a growth-adjusted basis vs. semiconductor peers. Upside: Direct AI data center interconnect beneficiary with analyst initiation momentum (Evercore Buy), no overhead resistance at all-time highs, and structural TAM expansion in CXL/PCIe switching. Risk: If NVDA disappoints tonight, this gives back the most as a high-beta AI derivative. Use fib 236 at $237.63 as stop — that’s 11% downside risk.

Avoid

SLS (+18.18%) — Trading at 6-month highs ahead of a binary clinical readout with no revenue and negative earnings. This is a coin-flip trade, not an investment. If the Phase 3 REGAL data misses, this revisits $4-5 (fib 500/618 levels). Only for biotech specialists who understand the AML data.

MXL (+4.78%) — Up 442% in six months with a 20-day low of $34.25 vs. current $99.39. The 50-day SMA at $43.59 is 56% below the current price — there is zero technical support nearby. At 51.6x forward P/E with negative EV/EBITDA, you’re paying for a story that must execute flawlessly. If any AI spending deceleration headline hits, this is the first name to unwind.

LSCC (+6.45%) — At 57.9x forward P/E with 241x EV/EBITDA, this is the most expensive name in the semiconductor peer group by a wide margin. Growth is solid at 42%, but the valuation is priced for perfection. Trading at 6-month highs with the 50-day SMA ($108.95) 18% below — chasing here offers poor risk/reward.

WSB Sentiment Check

NVDA — WSB says: BULLISH (80% bullish) Claude says: PARTIALLY AGREE — The sentiment matches the technical setup: NVDA at $224.68 is between support ($219 fib 236) and resistance ($254.94 fib 1.272), with the 50-day SMA ($195.52) well below. The bull case is intact IF they beat tonight, but 80% bullish ahead of an earnings binary event is exactly when WSB tends to be most exposed to a post-earnings sell-the-news. The asymmetry isn’t as good as the crowd thinks because guidance expectations are sky-high.

MU — WSB says: MIXED (55% bullish) Claude says: AGREE — Mixed is appropriate. MU at $725 is extraordinary (up from $201 six-month low), and the fib 236 support at $661 is 9% below. The stock is well below its 20-day high of $803, suggesting distribution. WSB’s split sentiment correctly reflects that this is a “show me” story — the AI memory thesis is real but the stock has already priced in 2-3 quarters of beats.

MSFT — WSB says: MIXED (55% bullish) Claude says: AGREE — MSFT at $416.59 is stuck in a range, well below its 6-month high of $490.90 and sitting near fib 618 support ($408). The 50-day SMA at $399.73 is the line in the sand. Mixed is exactly right — this is dead money until the next Azure AI catalyst, but it’s not broken.

NOW — WSB says: BEARISH (30% bullish) Claude says: AGREE — ServiceNow at $100.91 is in freefall, trading near its 6-month low of $83 and massively below every fib level (the fib 236 support is $152!). This stock has been cut in half from its highs. WSB is right to be bearish — something fundamental has broken here. Don’t catch this knife.

AMD — WSB says: MIXED (55% bullish) Claude says: PARTIALLY DISAGREE — I’d lean more bullish. AMD at $447.48 is near its 6-month high ($458.79) with the 50-day SMA at $292.90 confirming massive uptrend momentum. Fib 1.272 extension at $531.64 gives 19% upside. The chart is actually one of the strongest on the board. WSB’s 55% bullish undersells what is a confirmed breakout — the custom AI chip narrative (MI400 series) and data center GPU share gains are structural. More conviction warranted.

Earnings Scorecard

TOL — BEAT by 285% | Stock: +7.93% | Reported: Tuesday After Close Massive EPS beat ($13.16 vs. $3.42 est) — the housing cycle is turning and Toll Brothers is seeing high-end demand. Reaction seems actually muted for a 285% beat; suggests the market expected it or worries it’s peak earnings. Hold, don’t chase.

BILI — MISS by -57.6% | Stock: -7.30% | Reported: Tuesday Before Open EPS of $0.49 vs. $1.16 expected is a bad miss, but the headlines say “record profits” and “robust advertising” — the GAAP miss may be one-time charges vs. non-GAAP strength. At -7.3%, this looks like an overreaction if the advertising growth story is intact. Potential buy-the-dip, but verify the miss quality first.

MOD — BEAT by 17.7% | Stock: +5.30% | Reported: Tuesday Clean beat-and-raise from a thermal management/AI cooling play. $1.83 vs. $1.55 estimate. The +5.3% reaction to a 17.7% beat is proportional. Continuation trade if AI data center spending thesis holds.

CAVA — BEAT by 209% | Stock: +5.20% | Reported: Tuesday After Close Monster beat ($0.54 vs. $0.17) with raised 2026 outlook and strong traffic growth. The restaurant growth story is confirmed. +5.2% seems almost too modest for this magnitude of beat — could run further. Buy.

XP — MISS by -28.7% | Stock: +4.92% | Reported: Monday After Close EPS missed badly ($1.92 vs. $2.69) yet the stock rallied 5%? Classic “miss priced in” reaction — suggests the sell-side had sandbagged their published estimates or the forward guidance was strong. Don’t chase the relief rally; misses that rally often fade.

RYAAY — BEAT by 242.6% | Stock: +4.86% | Reported: Monday Before Open Ryanair’s record profit quarter with $4.74 vs. $1.38 estimate is stunning. European travel demand remains robust. +4.86% on a 242% beat is wildly muted — the market is pricing in fare pressure and fuel cost risks flagged in headlines. Could have legs on pullbacks.

HD — BEAT by 313.6% | Stock: +1.93% | Reported: Tuesday Before Open Home Depot’s $14.09 vs. $3.41 estimate is another comically large beat (likely share-based adjustments in the estimate methodology), but the headlines tell the real story: “profit falls as cost growth outpaces revenue” and “risk of missing 2026 guidance.” The +1.93% reaction on a technical beat with deteriorating fundamentals = sell-the-rip.

KEYS — BEAT by 166.8% | Stock: -0.18% | Reported: Tuesday After Close Keysight beat massively with record orders and raised outlook, yet the stock was flat. Classic “priced to perfection” reaction — the test & measurement space already ran into earnings. No edge here; hold.